

# Daphne Day

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1562841/daphne-day-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50  
papers

755  
citations

12  
h-index

26  
g-index

60  
ext. papers

1,140  
ext. citations

5.2  
avg, IF

4.16  
L-index

#	Paper	IF	Citations
50	COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study.. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2022</b> ,	1.9	2
49	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. <i>Vaccines</i> , <b>2022</b> , 10, 851	5.3	0
48	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
47	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259272	3.7	0
46	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , <b>2021</b> ,	6.4	1
45	Clinical dilemmas in local and regional testis cancer. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E58-E64	1.2	1
44	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	4
43	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1543-1551	8.7	7
42	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , <b>2021</b> , 11, 822-837	24.4	6
41	Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies. <i>Targeted Oncology</i> , <b>2021</b> , 16, 461-469	5	5
40	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1553-1562	2.2	13
39	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1563-1574	2.2	19
38	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	2
37	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5775-5782	4.8	2
36	Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. <i>Translational Oncology</i> , <b>2021</b> , 14, 100939	4.9	6
35	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , <b>2021</b> , 4, 289-296	6.7	2
34	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa122	4.6	5

33	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , <b>2021</b> , 28, 523-548	2.8	11
32	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 354-361	3.3	1
31	Out-of-pocket costs associated with head and neck cancer treatment. <i>Cancer Reports</i> , <b>2021</b> , e1528	1.5	1
30	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.. <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	1
29	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2021692	10.4	19
28	A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, 346-351	1.2	
27	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E537-E542	1.2	0
26	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3015-3022	4.8	6
25	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , <b>2020</b> , 105, 104666	4.4	3
24	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , <b>2020</b> , 28, 107-114	2.8	3
23	Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa050	4.6	0
22	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , <b>2020</b> , 138, 69-76	1.6	2
21	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors <b>2020</b> , 8,		12
20	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , <b>2020</b> , 12, 1317-1332	4.4	6
19	Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 585-588	3.7	7
18	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 112-120	7.5	5
17	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222359	3.7	4
16	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz071	4.6	2

15	The PD-1/PD-L1 pathway in advanced prostate cancer-have we milked this cow?. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, 346	3.2	5
14	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , <b>2019</b> , 125, 1341-1349	6.4	78
13	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , <b>2019</b> , 24, e518-e525	5.7	
12	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , <b>2018</b> , 122, 814-822	5.6	3
11	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, 59-66	1.2	8
10	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 43-57	14.4	11
9	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , <b>2017</b> , 71, 120-127	10.2	34
8	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 32918-32929	3.3	30
7	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , <b>2016</b> , 30, 571-584	7.9	66
6	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , <b>2016</b> , 8, 115	14.4	42
5	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109	14.4	149
4	Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3065-3065	2.2	1
3	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , <b>2016</b> , 34, 575-83	4.3	6
2	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , <b>2015</b> , 9, 997-1007	7.9	59
1	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , <b>2015</b> , 20, 653-9	5.7	18